Skye Bioscience Inc (SKYE) Stock Price, Quote & News

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 410 0266

Website: skyebioscience.com

Address:

11250 El Camino Real, Suite 100, San Diego, United States

Fellforit Mar. 21 at 2:20 AM

$SKYE shes gonna' blow!!

0 · Reply

MissionaryTrader Mar. 20 at 2:20 AM

$SKYE http://archive.fast-edgar.com/20260319/ALZZ6G2COC226Z9Z2W2B2ZZ2DTIMZ22IZO82

1 · Reply

TheMoneyDude777 Mar. 19 at 8:38 PM

$SKYE I just keep loading up on the inter day lows.

1 · Reply

Epafroditus Mar. 19 at 2:57 PM

$CHUC I am curious about news. But, I am patiënt. I know Henry will put it al together. Not one news item, when hé speaks there will be more. I like to be long on a stock. I believed $XXII was a good investment. Should have sold.... I believed $SKYE was an good investment... Should have sold also... But, for @chuc there is no change it is a mistake again. So I wait. We wait. Or if you read this, be Quick and Invest in this stock

1 · Reply

OfficialStocktwitsUser Mar. 18 at 6:53 PM

$SKYE RSI: 37.79, MACD: -0.0426 Vol: 0.04, MA20: 0.74, MA50: 0.85 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SkyeBioscience Mar. 17 at 12:01 PM

$SKYE continues to advance nimacimab as a potential differentiated therapy for obesity. Recent progress includes the initiation of the CBeyond Expansion Study, designed to evaluate higher exposures of nimacimab and generate additional safety and pharmacokinetic data to help inform optimal dose selection. In addition, the company has received written feedback from the FDA, which is guiding the planned Phase 2b clinical program. Together, these efforts represent important steps toward further defining nimacimab’s clinical potential and advancing Skye’s strategy to develop innovative therapies for obesity. Read more at: https://ir.skyebioscience.com/news-releases #Biotech #Obesity #ClinicalDevelopment #Weightloss

1 · Reply

TerzoMillennio Mar. 12 at 12:27 AM

$SKYE good job Aric.

1 · Reply

PLATINUM_TRADES Mar. 11 at 5:43 PM

$SKYE Heck of a bounce on the way back up 👆 nice

0 · Reply

OpenOutcrier Mar. 11 at 12:48 PM

$SKYE (-18.8% pre) Skye Bioscience GAAP EPS of -$0.36 misses by $0.06 https://ooc.bz/l/96290

0 · Reply

YazzJr Mar. 11 at 12:26 PM

$SKYE Yikes. Reverse split and most likely dilution after the split pretty much a guarantee now. That is if they can get anyone to buy the diluted shares. Bankruptcy becoming a real possibility for SKYE by year end. Sounded like the 300mg data is probably worthless as well.

1 · Reply

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 7:00 AM EST - 16 days ago

Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026

Feb 2, 2026, 1:26 PM EST - 6 weeks ago

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Feb 2, 2026, 7:00 AM EST - 6 weeks ago

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

Jan 29, 2026, 7:00 AM EST - 7 weeks ago

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Jan 21, 2026, 7:00 AM EST - 2 months ago

Skye Bioscience to Present Poster at Keystone Obesity Conference

Jan 16, 2026, 10:31 AM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 14, 2026, 10:31 AM EST - 2 months ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 12, 2026, 6:11 PM EST - 2 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 12, 2026, 7:00 AM EST - 2 months ago

Skye Provides 2026 Corporate Outlook

Jan 9, 2026, 9:45 AM EST - 2 months ago

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 5, 2026, 7:00 AM EST - 2 months ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

HALO

Dec 19, 2025, 2:56 PM EST - 3 months ago

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Dec 8, 2025, 7:11 AM EST - 3 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Nov 24, 2025, 7:00 AM EST - 4 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 10, 2025, 4:01 PM EST - 4 months ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Nov 5, 2025, 7:05 AM EST - 4 months ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:00 AM EST - 4 months ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Oct 28, 2025, 8:00 AM EDT - 5 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

Oct 6, 2025, 1:09 PM EDT - 5 months ago

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Oct 6, 2025, 10:39 AM EDT - 5 months ago

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Oct 6, 2025, 7:09 AM EDT - 5 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Sep 19, 2025, 2:19 PM EDT - 6 months ago

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 7:00 AM EDT - 6 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 5, 2025, 1:35 PM EDT - 7 months ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 4, 2025, 7:00 AM EDT - 7 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Aug 27, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 21, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 7, 2025, 4:01 PM EDT - 8 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Jul 30, 2025, 7:00 AM EDT - 8 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jun 23, 2025, 7:00 AM EDT - 9 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Fellforit Mar. 21 at 2:20 AM

$SKYE shes gonna' blow!!

0 · Reply

MissionaryTrader Mar. 20 at 2:20 AM

$SKYE http://archive.fast-edgar.com/20260319/ALZZ6G2COC226Z9Z2W2B2ZZ2DTIMZ22IZO82

1 · Reply

TheMoneyDude777 Mar. 19 at 8:38 PM

$SKYE I just keep loading up on the inter day lows.

1 · Reply

Epafroditus Mar. 19 at 2:57 PM

1 · Reply

OfficialStocktwitsUser Mar. 18 at 6:53 PM

0 · Reply

SkyeBioscience Mar. 17 at 12:01 PM

1 · Reply

TerzoMillennio Mar. 12 at 12:27 AM

$SKYE good job Aric.

1 · Reply

PLATINUM_TRADES Mar. 11 at 5:43 PM

$SKYE Heck of a bounce on the way back up 👆 nice

0 · Reply

OpenOutcrier Mar. 11 at 12:48 PM

$SKYE (-18.8% pre) Skye Bioscience GAAP EPS of -$0.36 misses by $0.06 https://ooc.bz/l/96290

0 · Reply

YazzJr Mar. 11 at 12:26 PM

1 · Reply

Polsky Mar. 11 at 11:33 AM

$SKYE hahahahaha darn great results :D I can't believe some of you are stil pumping this. What will they cure next? A nose pimple? :D

0 · Reply

PLATINUM_TRADES Mar. 10 at 11:32 PM

$SKYE I tried to short it.. Couldn't get it... Missed out on good money... We make money both ways in the Pitt🏟️🏟️

0 · Reply

Fellforit Mar. 10 at 10:10 PM

$SKYE is it buy, buy, buy or bye, bye, bye?? Come on pumpers, its on sale!! Skyerocketing after news....

0 · Reply

Fellforit Mar. 10 at 10:05 PM

$SKYE to the moon!!!! Same shit just different years and different names!!! Hahahahahahahaha..LIARS.....said basically all the same things when they were solving glaucoma

0 · Reply

MissionaryTrader Mar. 10 at 9:39 PM

$SKYE was it just me, or was anyone able to decipher what Punit’s response was to the Analyst’s question about when the 300mg trial data release will happen? It sounded like he said they don’t expect that data to be meaningful to their path forward.

1 · Reply

StocktwitsEarnings Mar. 10 at 9:19 PM

$SKYE Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.36 down -50.00% YoY • Skye Bioscience expects its current capital to fund projected operations and key clinical milestones through Q4 2026, excluding anticipated clinical and drug manufacturing costs for a proposed Phase 2b study.

0 · Reply

Jangalang Mar. 10 at 9:02 PM

$SKYE … I have been holding this stock so long that I have watched the ticker symbol change over five times and have been handed multiple reverse splits. Run far away from this scam company.

0 · Reply

Jangalang Mar. 10 at 9:01 PM

$SKYE … Tax loss end of 2026. This company has been dead. 😵

0 · Reply

quadacesAAAA Mar. 10 at 8:57 PM

$SKYE I lost money :(

0 · Reply

PLATINUM_TRADES Mar. 10 at 8:12 PM

$SKYE Heck of a loss... Don't like it

0 · Reply

SkyeBioscience Mar. 10 at 8:04 PM

Today, $SKYE reported its financial results for the fourth quarter and full year ended December 31, 2025 while also sharing a business update highlighting recent achievements and important milestones ahead. Read the release: https://ir.skyebioscience.com/news-releases/detail/255/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update #Biotech #Obesity #ClinicalDevelopment

0 · Reply

islandpunk Mar. 10 at 8:03 PM

$SKYE https://www.stocktitan.net/news/SKYE/skye-bioscience-reports-fourth-quarter-and-full-year-2025-financial-a4g0tvf2s5bp.html

0 · Reply

Market Cap	22.47M
Revenue (ttm)	0.00
Net Income (ttm)	-55.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	279,300
Avg Vol	637,350
Day's Range	N/A - N/A
Shares Out	33.38M
Stochastic %K	17%
Beta	2.86
Analysts	Strong Sell
Price Target	$8.71